Compliance for healthcare and care providers.

If the AI touches clinical workflow in any way, you’re likely in high-risk territory. If strictly admin, standard AI literacy and acceptable use policies apply.

No. MHRA regulates AI as a medical device. The EU AI Act is broader and covers governance, literacy, transparency, and deployer obligations. Both apply to AI-integrated clinical products.

CQC inspectors increasingly ask about digital governance, including AI use. Holding documented policies helps demonstrate the “Well-led” KLOE.

The Digital Omnibus political agreement narrowed and clarified scope in several places, eased some technical compliance burdens for general-purpose AI providers, and pushed the substantive obligations for most Annex III high-risk AI systems to December 2027. What it did not change: the Article 4 AI literacy obligations, the Article 50 transparency obligations, the prohibited-use rules, and the governance and documentation expectations placed on deployers. For UK businesses deploying AI tools, the baseline policy framework you need is essentially unchanged, and only the timetable for high-risk system technical conformity has moved.

Yes. The agreement pushes the substantive technical and conformity obligations for most Annex III high-risk AI systems to December 2027, giving providers more time to complete conformity assessments and CE marking. Transparency obligations (Article 50), AI literacy obligations (Article 4), prohibited-use rules, governance structures, and the documentation expected of deployers sit outside that extension and already apply. In practice the policy framework, Acceptable Use, AI Literacy, Article 50 disclosures, oversight SOPs and vendor registers, needs to be in place now, even if you are also a high-risk system provider working to a 2027 conformity deadline.

No. The Omnibus extended one specific timetable, substantive conformity for most Annex III high-risk systems, to December 2027. It did not defer the transparency, literacy, governance, or deployer documentation obligations. If your business uses AI tools (ChatGPT, Copilot, an internal copilot, an AI chatbot, AI-assisted recruitment or marketing), those obligations already apply to you rather than waiting until 2027. Waiting risks both regulatory exposure and PI questionnaire failure at renewal.

Annex III lists categories of AI systems treated as high-risk because of where they are used, not because of the underlying technology. These include AI used in: biometric identification and categorisation; critical infrastructure (water, gas, electricity, transport); education and vocational training (admissions, grading, proctoring); employment (recruitment, CV screening, performance evaluation, task allocation, termination); access to essential private and public services (credit scoring, insurance pricing, benefits eligibility, emergency dispatch); law enforcement, migration and border control; and administration of justice and democratic processes. If your AI sits in any of these workflows, even if it only assists a human decision, you are likely a high-risk deployer.

Yes. The Act applies extraterritorially. A UK business is in scope if it places an AI system on the EU market, if the output of its AI system is used in the EU, or if it employs or serves people in the EU or EEA. Brexit did not remove EU regulatory reach over UK businesses whose AI touches EU users, staff, or customers, much as UK GDPR continues to interact with EU data protection law for cross-border processing.

Enforcement of the EU AI Act is phased and already under way, and there is no grace period once an obligation applies to you. National regulators (in the UK, the ICO and sector regulators acting in cooperation with EU authorities) can investigate, request your documentation, and refer matters for fines. Penalties reach €15 million or 3% of global annual turnover (whichever is higher) for breaches of deployer and transparency obligations, and €35 million or 7% of global turnover for the most serious prohibited-use breaches. PI insurers are already asking for documented AI policies at renewal, so undocumented AI use can affect cover as well as expose you to enforcement.